These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization. Hokland SL; Horsman MR Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290 [TBL] [Abstract][Full Text] [Related]
5. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients. Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Horsman MR Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):859-66. PubMed ID: 18164835 [TBL] [Abstract][Full Text] [Related]
6. The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours. Chen G; Horsman MR; Pedersen M; Pang Q; Stødkilde-Jørgensen H Acta Oncol; 2008; 47(6):1071-6. PubMed ID: 18770061 [TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Li L; Rojiani AM; Siemann DW Acta Oncol; 2002; 41(1):91-7. PubMed ID: 11990525 [TBL] [Abstract][Full Text] [Related]
8. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS. Breidahl T; Nielsen FU; Stødkilde-Jørgensen H; Maxwell RJ; Horsman MR Acta Oncol; 2006; 45(3):306-16. PubMed ID: 16644574 [TBL] [Abstract][Full Text] [Related]
9. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Murata R; Overgaard J; Horsman MR Int J Radiat Biol; 2001 Feb; 77(2):195-204. PubMed ID: 11236926 [TBL] [Abstract][Full Text] [Related]
10. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. Ley CD; Horsman MR; Kristjansen PE Neoplasia; 2007 Feb; 9(2):108-12. PubMed ID: 17356706 [TBL] [Abstract][Full Text] [Related]
11. Combination of vascular targeting agents with thermal or radiation therapy. Horsman MR; Murata R Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1518-23. PubMed ID: 12459380 [TBL] [Abstract][Full Text] [Related]
12. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Murata R; Horsman MR Int J Hyperthermia; 2004 Jun; 20(4):393-404. PubMed ID: 15204520 [TBL] [Abstract][Full Text] [Related]
15. Combretastatin-induced hypertension and the consequences for its combination with other therapies. Busk M; Bohn AB; Skals M; Wang T; Horsman MR Vascul Pharmacol; 2011; 54(1-2):13-7. PubMed ID: 21040805 [TBL] [Abstract][Full Text] [Related]
16. Use of tetrahydraindazolone dicarboxylic acid (HIDA) to improve the therapeutic effect in vivo of combined cisplatin, heat and radiation treatment. Overgaard J; Radacic M; Skaric D; Skaric V; Horsman MR; Lindegaard JC; Jercic J Int J Hyperthermia; 1993; 9(6):821-30. PubMed ID: 8106823 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of anti-vascular therapy with texture analysis. Chen G; Jespersen S; Pedersen M; Pang Q; Horsman MR; Stødkilde Jørgensen H Anticancer Res; 2005; 25(5):3399-405. PubMed ID: 16101155 [TBL] [Abstract][Full Text] [Related]
18. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Hill SA; Chaplin DJ; Lewis G; Tozer GM Int J Cancer; 2002 Nov; 102(1):70-4. PubMed ID: 12353236 [TBL] [Abstract][Full Text] [Related]
19. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Chaplin DJ; Pettit GR; Hill SA Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542 [TBL] [Abstract][Full Text] [Related]
20. Vascular targeting: a potential additional anti-cancer treatment. Lambin P; Landuyt W Verh K Acad Geneeskd Belg; 2003; 65(1):29-46. PubMed ID: 12802895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]